Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
CimetidineCat. No. 0902 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-Cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine |
Biological Activity
Widely used H2 histamine antagonist which has more recently been described as an inverse agonist. Also a potent I1 imidazoline binding site ligand.Certificate of Analysis / Safety Data Sheet
References
Hill (1990) Distribution, properties and functional characteristics of three classes of histamine receptor. Pharmacol.Rev. 42 45. PMID: 2164693.
Ernsberger et al (1992) A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J.Cardiovasc.Pharmacol. 20 S1.
Tsoli et al (1995) The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of langerhans. Eur.J.Pharmacol. 284 199. PMID: 8549627.
Smit et al (1996) Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active receptors. Proc.Natl.Acad.Sci.U.S.A. 93 6802. PMID: 8692899.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Cimetidine, supplier, I1, agonists, histamine, H2, antagonists, inverse, Imidazoline, Receptors, histaminergic
Quick Order
Find multiple products by catalog number
Histamine Review
Written by Iwan de Esch and Rob Leurs, leading experts. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
New Products in this Area
Selective H4 agonist
Tocris Events
Win a Kindle
11th Congress of the French Neuroscience Society
May 21 - 24, 2013
Lyon, France
Booth Number: 32